BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
3/16/2026 8:22:58 AM | Browse: 44 | Download: 154
 |
Received |
|
2025-09-23 09:00 |
|
Peer-Review Started |
|
2025-09-23 09:00 |
|
First Decision by Editorial Office Director |
|
2025-10-17 06:19 |
|
Return for Revision |
|
2025-10-17 06:19 |
|
Revised |
|
2025-11-16 07:43 |
|
Publication Fee Transferred |
|
2025-11-28 05:50 |
|
Second Decision by Editor |
|
2026-01-08 02:38 |
 |
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-01-08 09:37 |
|
Articles in Press |
|
2026-01-08 09:37 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-02-28 08:01 |
|
Publish the Manuscript Online |
|
2026-03-16 08:22 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2026. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Basic Study |
| Article Title |
Icariin inhibits tumor-associated neutrophil recruitment via the CXCL8-CXCR2 axis and restrains pro-metastatic programs in colorectal cancer
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Yan-Hua Zhao, Juan Chen, Tao Gong, Hai-Yan Ge and Min Li |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Min Li, PhD, Department of Oncology, Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, No. 157 Daming Road, Nanjing 210022, Jiangsu Province, China. limin_2024@163.com |
| Key Words |
Icariin; Neutrophils; Recruitment; C-X-C motif chemokine ligand 8-C-X-C motif chemokine receptor 2 axis; Colorectal cancer; Pro-metastatic program; Progression |
| Core Tip |
This study elucidates a novel mechanism by which the natural compound icariin (ICA) combats colorectal cancer. We demonstrate that ICA upregulates the tumor suppressor SMAD4, thereby inhibiting the production of C-X-C motif chemokine ligand 8 (CXCL8) and other C-X-C motif chemokine receptor 2 (CXCR2)-associated chemokines. This action predominantly limits the recruitment of tumor-associated neutrophils (TANs) via the CXCL8-CXCR2 axis. Notably, ICA not only reduces neutrophil infiltration but also reprograms TANs toward an antitumor N1 phenotype. By disrupting this SMAD4-CXCL8-CXCR2-TAN axis, ICA effectively restrains epithelial-mesenchymal transition and other pro-metastatic processes, positioning it as a promising therapeutic candidate with a distinct immunomodulatory strategy against colorectal cancer progression. |
| Publish Date |
2026-03-16 08:22 |
| Citation |
Zhao YH, Chen J, Gong T, Ge HY, Li M. Icariin inhibits tumor-associated neutrophil recruitment via the CXCL8-CXCR2 axis and restrains pro-metastatic programs in colorectal cancer. World J Gastroenterol 2026; 32(11): 113325 |
| URL |
https://www.wjgnet.com/1007-9327/full/v32/i11/113325.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v32.i11.113325 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
